Cannabinoformins: Designing Biguanide-Embedded, Orally Available, Peripherally Selective Cannabinoid-1 Receptor Antagonists for Metabolic Syndrome Disorders

Dvorácskó, Szabolcs and Herrerias, A. and Oliverio, A. and Bhattacharjee, P. and Pommerolle, L. and Liu, Z. and Feng, D. and Lee, Y.-S. and Hassan, S.A. and Godlewski, G. and Cinar, R. and Iyer, M.R. (2023) Cannabinoformins: Designing Biguanide-Embedded, Orally Available, Peripherally Selective Cannabinoid-1 Receptor Antagonists for Metabolic Syndrome Disorders. JOURNAL OF MEDICINAL CHEMISTRY, 66 (17). pp. 11985-12004. ISSN 0022-2623

Text dvoracsko-et-al-2023-cannabinoformins-designing-biguanide-embedded-orally-available-peripherally-selective-cannabinoid.pdf - Published Version Restricted to Registered users only Download (7MB) | Request a copy

Abstract

We have designed orally bioavailable, non-brain-penetrant antagonists of the cannabinoid-1 receptor (CB1R) with a built-in biguanide sensor to mimic 5′-adenosine monophosphate kinase (AMPK) activation for treating obesity-associated co-morbidities. A series of 3,4-diarylpyrazolines bearing rational pharmacophoric pendants designed to limit brain penetration were synthesized and evaluated in CB1R ligand binding assays and recombinant AMPK assays. The compounds displayed high CB1R binding affinity and potent CB1R antagonist activities and acted as AMPK activators. Select compounds showed good oral exposure, with compounds 36, 38-S, and 39-S showing <5% brain penetrance, attesting to peripheral restriction. In vivo studies of 38-S revealed decreased food intake and body weight reduction in diet-induced obese mice as well as oral in vivo efficacy of 38-S in ameliorating glucose tolerance and insulin resistance. The designed “cannabinoformin” four-arm CB1R antagonists could serve as potential leads for treatment of metabolic syndrome disorders with negligible neuropsychiatric side effects. © 2023 by American Chemical Society.

Actions (login required)

Edit Item